Wegener's granulomatosis;Granulomatose de Wegener

Presse Medicale

Volumn 36, Issue 5 II, 2007, Pages 860-874

  Pagnoux, Christian ^a   Teixeira, Luis ^a  

^a Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AZATHIOPRINE; BENZOCAINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFECTIVE AGENT;

B LYMPHOCYTE; CLINICAL FEATURE; CYTOKINE RELEASE; DENDRITIC CELL; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; GLOMERULONEPHRITIS; GRANULOMATOUS INFLAMMATION; HEREDITY; HISTOLOGY; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFECTION; KIDNEY BIOPSY; LOWER RESPIRATORY TRACT; LYMPHOCYTE; NEUROLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; RADIODENSITOMETRY; RELAPSE; REMISSION; SERUM; SHORT SURVEY; T LYMPHOCYTE; UPPER RESPIRATORY TRACT; UROLOGY; VASCULITIS; VEIN THROMBOSIS; WEGENER GRANULOMATOSIS; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; MORTALITY; RADIOGRAPHY; SEX DIFFERENCE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; B-LYMPHOCYTES; CHILD; DENDRITIC CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; SEX FACTORS; T-LYMPHOCYTES; TOMOGRAPHY, X-RAY COMPUTED; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; WEGENER GRANULOMATOSIS;

EID: 34247348689     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.02.015     Document Type: Short Survey

References (97)

1. Godman G.C., and Churg J. Wegener's granulomatosis: pathology and review of the literature. AMA Arch Pathol 58 (1954) 533-553
2. Leavitt R.Y., Fauci A.S., Bloch D.A., Michel B.A., Hunder G.G., Arend W.P., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33 (1990) 1101-1107
3. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 (1994) 187-192
4. Anderson G., Coles E.T., Crane M., Douglas A.C., Gibbs A.R., Geddes D.M., et al. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. QJM 83 (1992) 427-438
5. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
6. Reinhold-Keller E., Beuge N., Latza U., de Groot K., Rudert H., Nolle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43 (2000) 1021-1032
7. Lie J.T. Wegener's granulomatosis: histological documentation of common and uncommon manifestations in 216 patients. Vasa 26 (1997) 261-270
8. Walton E.W. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ (1958) 2265-2270
9. de Groot K., Schmidt D.K., Arlt A.C., Gross W.L., and Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 58 (2001) 1215-1221
10. Nishino H., Rubino F.A., DeRemee R.A., Swanson J.W., and Parisi J.E. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 33 (1993) 4-9
11. Aasarod K., Iversen B.M., Hammerstrom J., Bostad L., Vatten L., and Jorstad S. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 15 (2000) 611-618
12. Guillevin L., Cordier J.F., Lhote F., Cohen P., Jarrousse B., Royer I., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40 (1997) 2187-2198
13. Matteson E.L., Gold K.N., Bloch D.A., and Hunder G.G. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 101 (1996) 129-134
14. Cotch M.F., Hoffman G.S., Yerg D.E., Kaufman G.I., Targonski P., and Kaslow R.A. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 39 (1996) 87-92
15. Oliveira G.H., Seward J.B., Tsang T.S., and Specks U. Echocardiographic findings in patients with Wegener granulomatosis. Mayo Clin Proc 80 (2005) 1435-1440
16. Abdou N.I., Kullman G.J., Hoffman G.S., Sharp G.C., Specks U., McDonald T., et al. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 29 (2002) 309-316
17. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42 (1999) 2666-2673
18. Fauci A.S., Haynes B.F., Katz P., and Wolff S.M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98 (1983) 76-85
19. Haugeberg G., Bie R., Bendvold A., Larsen A.S., and Johnsen V. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 17 (1998) 364-368
20. Watts R.A., Lane S., and Scott D.G. What is known about the epidemiology of the vasculitides?. Best Pract Res Clin Rheumatol. 19 (2005) 191-207
21. Koldingsnes W., and Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 43 (2000) 2481-2487
22. Reinhold-Keller E., Herlyn K., Wagner-Bastmeyer R., and Gross W.L. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 53 (2005) 93-99
23. Lane S.E., Watts R.A., Bentham G., Innes N.J., and Scott D.G. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 48 (2003) 814-823
24. Esnault V.L., Testa A., Audrain M., Rogé C., Hamidou M., Barrier J.H., et al. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 43 (1993) 1329-1332
25. Jagiello P., Gross W.L., and Epplen J.T. Complex genetics of Wegener granulomatosis. Autoimmun Rev 4 (2005) 42-47
26. Griffith M.E., and Pusey C.D. HLA genes in ANCA-associated vasculitides. Exp Clin Immunogenet 14 (1997) 196-205
27. Schreiber A., Busjahn A., Luft F.C., and Kettritz R. Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 14 (2003) 68-75
28. Jagiello P., Gencik M., Arning L., Wieczorek S., Kunstmann E., Csernok E., et al. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 114 (2004) 468-477
29. Jagiello P., Aries P., Arning L., Wagenleiter S.E., Csernok E., Hellmich B., et al. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 52 (2005) 4039-4043
30. Zhou Y., Huang D., Paris P.L., Sauter C.S., Prock K.A., and Hoffman G.S. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum 50 (2004) 2645-2650
31. Stegeman C.A., Tervaert J.W., Sluiter W.J., Manson W.L., de Jong P.E., and Kallenberg C.G. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120 (1994) 12-17
32. Falk R.J., Terrell R.S., Charles L.A., and Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87 (1990) 4115-4119
33. Lu X., Garfield A., Rainger G.E., Savage C.O., and Nash G.B. Mediation of endothelial cell damage by serine proteases, but not superoxide, released from antineutrophil cytoplasmic antibody-stimulated neutrophils. Arthritis Rheum 54 (2006) 1619-1628
34. Pfister H., Ollert M., Frohlich L.F., Quintanilla-Martinez L., Colby T.V., Specks U., et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104 (2004) 1411-1418
35. Pendergraft III W.F., Preston G.A., Shah R.R., Tropsha A., Carter Jr. C.W., Jennette J.C., et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 10 (2004) 72-79
36. Filer A.D., Gardner-Medwin J.M., Thambyrajah J., Raza K., Carruthers D.M., Stevens R.J., et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 62 (2003) 162-167
37. Woywodt A., Goldberg C., Kirsch T., de Groot K., Erdbruegger U., Haller H., et al. Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis. Ann Rheum Dis 65 (2006) 164-168
38. Holmen C., Christensson M., Pettersson E., Bratt J., Stjarne P., Karrar A., et al. Wegener's granulomatosis is associated with organ-specific antiendothelial cell antibodies. Kidney Int 66 (2004) 1049-1060
39. Csernok E., Trabandt A., Muller A., Wang G.C., Moosig F., Paulsen J., et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 42 (1999) 742-750
40. Lamprecht P., Moosig F., Csernok E., Seitzer U., Schnabel A., Mueller A., et al. CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 56 (2001) 751-757
41. Steiner K., Moosig F., Csernok E., Selleng K., Gross W.L., Fleischer B., et al. Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol 126 (2001) 143-150
42. Krumbholz M., Specks U., Wick M., Kalled S.L., Jenne D., and Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 25 (2005) 298-302
43. Voswinkel J., Muller A., and Lamprecht P. Is PR3-ANCA Formation Initiated in Wegener's Granulomatosis Lesions? Granulomas as Potential Lymphoid Tissue Maintaining Autoantibody Production. Ann N Y Acad Sci (2005) 105112-105119
44. Megiovanni A.M., Sanchez F., Robledo-Sarmiento M., Morel C., Gluckman J.C., and Boudaly S. Polymorphonuclear neutrophils deliver activation signals and antigenic molecules to dendritic cells: a new link between leukocytes upstream of T lymphocytes. J Leukoc Biol 79 (2006) 977-988
45. Csernok E., Ai M., Gross W.L., Wicklein D., Petersen A., Lindner B., et al. Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood 107 (2006) 4440-4448
46. van Rossum A.P., Pas H.H., Fazzini F., Huitema M.G., Limburg P.C., Jonkman M.F., et al. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 54 (2006) 986-991
47. Bjerkeli V., Halvorsen B., Damas J.K., Nordoy I., Yndestad A., Aukrust P., et al. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis. Ann Rheum Dis 63 (2004) 1659-1663
48. Devaney K.O., Travis W.D., Hoffman G., Leavitt R., Lebovics R., and Fauci A.S. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 14 (1990) 555-564
49. Gluth M.B., Shinners P.A., and Kasperbauer J.L. Subglottic stenosis associated with Wegener's granulomatosis. Laryngoscope 113 (2003) 1304-1307
50. Seror R., Mahr A., Ramanoelina J., Pagnoux C., Cohen P., and Guillevin L. Central nervous system involvement in Wegener granulomatosis. Medicine (Baltimore) 85 (2006) 54-65
51. Nishino H., Rubino F.A., and Parisi J.E. The spectrum of neurologic involvement in Wegener's granulomatosis. Neurology 43 (1993) 1334-1337
52. Francès C., Lê Thi Huong D., Piette J.C., Saada V., Boisnic S., Wechsler B., et al. Wegener's granulomatosis. Dermatological manifestations in 75 cases with clinicopathologic correlation. Arch Dermatol 130 (1994) 861-867
53. Barksdale S.K., Hallahan C.W., Kerr G.S., Fauci A.S., Stern J.B., and Travis W.D. Cutaneous pathology in Wegener's granulomatosis. A clinicopathologic study of 75 biopsies in 46 patients. Am J Surg Pathol 19 (1995) 161-172
54. Forstot J.Z., Overlie P.A., Neufeld G.K., Harmon C.E., and Forstot S.L. Cardiac complications of Wegener granulomatosis: a case report of complete heart block and review of the literature. Semin Arthritis Rheum 10 (1980) 148-154
55. Storesund B., Gran J.T., and Koldingsnes W. Severe intestinal involvement in Wegener's granulomatosis: report of two cases and review of the literature. Br J Rheumatol 37 (1998) 387-390
56. Pagnoux C., Mahr A., Cohen P., and Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, wegener granulomatosis, churg-strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 84 (2005) 115-128
57. Kumar A., Mohan A., Gupta R., Singal V.K., and Garg O.P. Relapse of Wegener's granulomatosis in the first trimester of pregnancy: a case report. Br J Rheumatol 37 (1998) 331-333
58. Auzary C., Huong D.T., Wechsler B., Vauthier-Brouzes D., and Piette J.C. Pregnancy in patients with Wegener's granulomatosis: report of five cases in three women. Ann Rheum Dis 59 (2000) 800-804
59. Merkel P.A., Lo G.H., Holbrook J.T., Tibbs A.K., Allen N.B., Davis Jr. J.C., et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142 (2005) 620-626
60. Raza K., Thambyrajah J., Townend J.N., Exley A.R., Hortas C., Filer A., et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease?. Circulation 102 (2000) 1470-1472
61. Stone J.H. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 48 (2003) 2299-2309
62. Nolle B., Specks U., Ludemann J., Rohrbach M.S., DeRemee R.A., and Gross W.L. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 111 (1989) 28-40
63. von Scheven E., Lee C., and Berg B.O. Pediatric Wegener's granulomatosis complicated by central nervous system vasculitis. Pediatr Neurol 19 (1998) 317-319
64. Bakthavachalam S., Driver M.S., Cox C., Spiegel J.H., Grundfast K.M., and Merkel P.A. Hearing loss in Wegener's granulomatosis. Otol Neurotol 25 (2004) 833-837
65. Collins M.P., Mendell J.R., Periquet M.I., Sahenk Z., Amato A.A., Gronseth G.S., et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 55 (2000) 636-643
66. Sanders J.S., Slot M.C., and Stegeman C.A. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003) 2072-2073 (author reply 2072-3)
67. Seo P., Min Y.I., Holbrook J.T., Hoffman G.S., Merkel P.A., Spiera R., et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 52 (2005) 2168-2178
68. Bligny D., Mahr A., Toumelin P.L., Mouthon L., and Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 51 (2004) 83-91
69. Westman K.W., Selga D., Isberg P.E., Bladstrom A., and Olsson H. High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 14 (2003) 2926-2933
70. Koldingsnes W., and Nossent J.C. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 30 (2003) 80-88
71. Hogan S.L., Falk R.J., Chin H., Cai J., Jennette C.E., Jennette J.C., et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143 (2005) 621-631
72. Kyndt X., Reumaux D., Bridoux F., Tribout B., Bataille P., Hachulla E., et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 106 (1999) 527-533
73. Slot M.C., Tervaert J.W., Boomsma M.M., and Stegeman C.A. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 51 (2004) 269-273
74. Stegeman C.A. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 17 (2002) 2077-2080
75. Boomsma M.M., Stegeman C.A., van der Leij M.J., Oost W., Hermans J., Kallenberg C.G., et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43 (2000) 2025-2033
76. Lurati-Ruiz F., and Spertini F. Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis. J Rheumatol 32 (2005) 2167-2172
77. Tervaert J.W., Huitema M.G., Hene R.J., Sluiter W.J., The T.H., van der Hem G.K., et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 336 (1990) 709-711
78. Jayne D. How to induce remission in primary systemic vasculitis. Best Pract Res Clin Rheumatol. 19 (2005) 293-305
79. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniene J., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003) 36-44
80. Langford C.A., Klippel J.H., Balow J.E., James S.P., and Sneller M.C. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 129 (1998) 49-58
81. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114 (2003) 463-469
82. Nowack R., Gobel U., Klooker P., Hergesell O., Andrassy K., and van der Woude F.J. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10 (1999) 1965-1971
83. Langford C.A., Talar-Williams C., and Sneller M.C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 51 (2004) 278-283
84. Koukoulaki M., and Jayne D.R. Mycophenolate Mofetil in Anti-Neutrophil Cytoplasm Antibodies-Associated Systemic Vasculitis. Nephron Clin Pract 102 (2005) c100-c107
85. de Groot K., Reinhold-Keller E., Tatsis E., Paulsen J., Heller M., Nolle B., et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 39 (1996) 2052-2061
86. Stegeman C.A., Tervaert J.W., de Jong P.E., and Kallenberg C.G. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335 (1996) 16-20
87. Hoffman G.S. Immunosuppressive therapy is always required for the treatment of limited Wegener's granulomatosis. Sarcoidosis Vasc Diffuse Lung Dis 13 (1996) 249-252
88. Hoffman G.S., Leavitt R.Y., Kerr G.S., and Fauci A.S. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35 (1992) 1322-1329
89. De Groot K., Rasmussen N., Bacon P.A., Tervaert J.W., Feighery C., Gregorini G., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 2461-2469
90. Jayne D.R., Chapel H., Adu D., Misbah S., O'Donoghue D., Scott D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93 (2000) 433-439
91. Guillevin L., and Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial 7 (2003) 155-160
92. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNF-α blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 (2004) 717-721
93. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41 (2002) 1126-1132
94. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
95. Stasi R., Stipa E., Poeta G.D., Amadori S., Newland A.C., and Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45 (2006) 1432-1436
96. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., and Specks U. Rituximab for Refractory Wegener's Granulomatosis: Report of A Prospective, Open-Label Pilot Trial. Am J Respir Crit Care Med 173 (2005) 180-187
97. Schmitt W.H., Hagen E.C., Neumann I., Nowack R., Flores-Suarez L.F., and van der Woude F.J. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65 (2004) 1440-1448